Seeking Alpha

Avanir prevails in patent case

  • The U.S. District Court for the District of Delaware rules in favor of Avanir Pharmaceuticals (AVNR +1.5%) in its patent infringement case against Par Pharmaceuticals and Impax Laboratories (IPXL -1.3%) regarding their ANDAs for generic versions of Nuedexta.
  • The judge upheld the validity of patents '282 and '484 and ruled the proposed formulations infringe on both of them.
  • Nuedexta is the only FDA-approved product for the treatment of pseudobulbar effect. Based on the court's decision, the product has 12 years of market exclusivity remaining.
Comments (2)
  • fidelity comment
    , contributor
    Comments (84) | Send Message
    This happened last week and was reported on by SA. What new news has occurred to issue the current blurb?

    5 May, 04:48 PM Reply Like
  • Leont68
    , contributor
    Comments (1357) | Send Message
    today, they formally filed a 8k announcing the win.
    5 May, 04:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: